Zepbound (Tirzepatide): What It Is, Results & How to Get It (2026)

Zepbound is Eli Lilly's brand of tirzepatide, a once-weekly injection that activates both the GLP-1 and GIP hormone receptors. The FDA approved it on November 8, 2023 for chronic weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-1 trial (NEJM 2022) people on the 15 mg dose lost an average of 20.9% of their body weight over 72 weeks.

You need a prescription from a licensed clinician: your own doctor, or a telehealth provider after an online assessment. The prescription can be filled at a retail pharmacy (list price $1,086/month, or as little as $25/month with commercial coverage and the Lilly savings card), through Eli Lilly's LillyDirect self-pay pharmacy ($299–$449/month by dose), or under the Medicare GLP-1 Bridge at $50/month for eligible Part D enrollees, which launched July 1, 2026.

Yes. LillyDirect, Eli Lilly's own online pharmacy, ships Zepbound vials and KwikPens after a prescription from your doctor or an independent telehealth prescriber it connects you with. Telehealth providers we track that list brand Zepbound include MEDVi, ShedRx, GobyMeds, MEDGm, Sesame Care; they charge their own visit or membership fee on top of the medication. No legitimate seller ships Zepbound without a prescription.

In SURMOUNT-1 (NEJM 2022), adults without diabetes lost an average of 15% of body weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks, against 3.1% on placebo. For a 250-pound person, 20.9% is about 52 pounds. Results vary, and most people regain weight if they stop treatment.

Zepbound's list price is $1,086 per month at every dose (Eli Lilly, pricinginfo.lilly.com). LillyDirect self-pay costs $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg if you refill within 45 days. With commercial coverage the savings card can bring it to $25/month, and eligible Medicare enrollees pay $50/month. Compounded tirzepatide from tracked providers costs $119–$399/month.

Zepbound and Mounjaro contain the same molecule, tirzepatide, made by Eli Lilly, in the same doses (2.5 mg to 15 mg weekly). Mounjaro was approved in May 2022 for type 2 diabetes; Zepbound was approved in November 2023 for weight management. Insurance coverage, list price ($1,112 for Mounjaro) and the LillyDirect self-pay offer differ; LillyDirect self-pay pricing applies to Zepbound.

In their pivotal trials, tirzepatide produced more weight loss than semaglutide: 20.9% at 72 weeks for Zepbound 15 mg in SURMOUNT-1 (NEJM 2022) against 14.9% at 68 weeks for Wegovy 2.4 mg in STEP 1 (NEJM 2021). The SURMOUNT-5 head-to-head trial (NEJM 2025) also found greater weight loss with tirzepatide. Both are FDA-approved; Wegovy also comes as a daily pill and has a cardiovascular indication.

Compounded tirzepatide uses the same active ingredient but is not Zepbound: it is prepared by a licensed compounding pharmacy for an individual prescription and is not an FDA-approved finished product, so the FDA has not reviewed it for safety, effectiveness or quality. It costs less, $119/month at the low end from Embody and SnagRx in our data, against $299+ for brand Zepbound through LillyDirect.

Zepbound starts at 2.5 mg once a week for four weeks, then increases by 2.5 mg every four weeks or more as tolerated. The maintenance doses are 5 mg, 10 mg or 15 mg; 15 mg is the maximum. The 2.5 mg starting dose is for acclimation, not weight loss. It is injected under the skin of the stomach, thigh or upper arm on the same day each week.

The most common side effects are gastrointestinal: in SURMOUNT-1 roughly 28% of participants on tirzepatide reported nausea, 22% diarrhea, 16% constipation and 12% vomiting, mostly mild and worst after dose increases. Zepbound carries an FDA boxed warning for thyroid C-cell tumors seen in rodents and must not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis and gallbladder problems are rare but serious.